The personalized cancer therapy study described in Module...

Key Concepts

Clinical Study Design

Clinical study design in personalized therapy extends initial case observations to larger patient groups by incorporating rigorous data collection, statistical validation, and control groups. This design ensures that hypotheses generated from individual cases, such as unusual responses to treatment, are tested in a systematic way to confirm their broader applicability and to uncover any unexpected results.

Biomarker Discovery

Biomarker discovery is the process of identifying biological markers that can predict treatment response or disease progression. In the setting of personalized cancer therapy, analyzing data from cases with unusual responses can help identify specific genetic or protein markers that not only explain the individual patient’s response but also can be used to select appropriate therapies for other patients.

Translational Research

Translational research bridges the gap between laboratory-based discoveries and clinical applications. In the context of personalized cancer therapy, it involves integrating data from detailed case studies with larger clinical trials to understand the underlying biological mechanisms of drug response and to develop new, targeted treatments based on these insights.

Exceptional Responder Analysis

Exceptional responder analysis focuses on understanding why certain patients experience unusually favorable outcomes with a particular therapy. This approach examines detailed molecular and genetic data from these outliers to identify potential biomarkers or molecular mechanisms that could predict response, and it aids in refining therapeutic strategies for the broader patient population.

Personalized Medicine

Personalized medicine involves tailoring treatment strategies based on an individual patient's unique genetic, molecular, or phenotypic characteristics. In cancer therapy, this approach is crucial as it helps identify tumors that might respond to specific drugs, allowing clinicians to optimize treatment plans and improve patient outcomes.

Transcript

00:01 Situation where it's coming out of module 8 .10, where it's talking about personalized cancer therapy.

00:08 You have a beginning of a bladder cancer and then you use a drug.

00:12 And one patient responds really well and other people not quite as well.

00:17 And it's asking various questions.

00:20 For example, how could the approach be expanded or extended from table 8 -10? second one do you see any unusual results it might not have another round of studies and then third highlights such a study be designed and so on so the first thing is to understand what's happening it's helpful to understand how cancer cells grow in the first place in order to be able to understand how targeted therapy works so there are cells in every tissue of your body there's different cell types of blood cells, brain cells, skin cells, all these different cells.

01:08 And, of course, each of these different cells have a specific function.

01:12 And so there are ways in which that your body are able to make duplicates or copies when their body cells, like in the bladder, they're going to be identical.

01:25 And so it goes through this process of the cell cycle, and then division is the mitosis.

01:34 Mitosis is about this.

01:36 Oh, here we go.

01:36 It's the m.

01:37 Here it is.

01:38 It's about this small portion, maybe 15 % out of the whole entire cell cycle.

01:44 And what happens is that there are certain signals, certain checkpoints along the way that the cell gets a message, some sort of a growth factor to say, oh, we need to be rapidly dividing.

01:59 Or we need to slow our division down.

02:02 A tumor basically is a mass of abnormally growing cells that are growing within a normal life, otherwise normal tissue.

02:11 It's your own cells.

02:13 However, maybe that there is a mutation in the mutation in the genetic setup of a beginning or a progenitor cell, and the mutation along the gene, genomic sequence tells these proteins, the cancer growth factor tells the receptive proteins, hey, even though everybody else has stopped dividing, we got to keep going.

02:39 And so the proteins have changed to where they continue the signals of one of those checkpoints, where it's basically telling the cell to continue to divide, continue to divide, and be rapidly dividing, and it continued when everybody else has stopped around them.

02:59 And so benign or malignant tumors are the kinds of tumors that can grow out of this.

03:06 The nine tumors are the ones that they maintain themselves at that original site, and they are not considered as malignant or cancerous tumors because they don't send out these seeds or these little outcroppings to spread to other organs.

03:25 They just maintain and they stay in that particular organ, and that they can grow in size and cause.

03:34 A disruption of function solely based on the fact that they are a growth and that they're a certain size and it inhibits the probability that the organ is going to do their main job.

03:49 However, when a person has a malignant tumor, this is where metastasis takes place and this is where they are having growths in a ton of other places and the spreading of the different tumors is called menestasis.

04:08 It comes back and it's like okay it hasn't spread yet but this is one that we know that does spread they can also be removed surgically and then treated with concentrations of high beams of radiation or also the chemotherapy the chemical chemo chemical chemotherapy now one of the things that we have increased in the last few years is to personalize the cancer treatment.

04:38 Instead of just an automatic, one, two, three...

Please give Ace some feedback